Skip to main content
Biocure Technology Inc. logo

Biocure Technology Inc. — Investor Relations & Filings

Ticker · CURE.X ISIN · CA09075T1075 LEI · 529900KSL59IBBDYBU95 CSE Manufacturing
Open in API
Filings indexed 149 across all filing types
Latest filing 2021-08-31 Regulatory Filings
Country CA Canada
Listing CSE CURE.X

About Biocure Technology Inc.

https://biocuretech.com/

Biocure Technology Inc. is a biopharmaceutical company specializing in the development and commercialization of advanced biological medicines. The company's core focus areas include proprietary CAR T-cell therapies designed to treat various cancers, such as leukemia, lung, and breast cancer. Concurrently, Biocure is engaged in the development and commercialization of major biosimilar pharmaceutical products, aiming to improve the accessibility of complex biological treatments. Furthermore, the company pursues novel, highly-efficacious therapies for severe diseases caused by RNA viruses where significant unmet medical needs exist.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings for a venture issuer, signed by the CEO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2021. The document is primarily a certification letter and does not contain actual financial statements or substantive financial data. It references the interim filings but does not include them. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is short (3034 characters), consistent with a certification letter rather than a full report.
2021-08-31 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus or brochure describing the terms and conditions of redeemable income notes (billets à revenu rachetables) issued by Banque de Montréal (BMO). It includes detailed financial product features such as coupon payments, redemption terms, index references, risk factors, and hypothetical scenarios illustrating potential returns. The document is not a financial report, earnings release, or regulatory filing but rather a detailed offering document for a structured financial product. It is not an announcement or brief summary but a comprehensive product brochure. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to the issuance and terms of a financial instrument (redeemable notes).
2021-07-22 English
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a press release announcing the closing of a financing round by BioCure Technology Inc. It details the private placement of units, including shares and warrants, the amount raised, and the intended use of proceeds. There are no financial statements or detailed financial analysis present, and the document is relatively short (3834 characters). It is not an annual or interim report, nor an earnings release. It is not a regulatory filing or certification. The content clearly fits the category of a Capital/Financing Update, as it provides information about fundraising activities and capital structure changes.
2021-07-15 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management’s Discussion & Analysis As at March 31, 2021' and contains detailed narrative on the company's operations, financial position, business risks, product portfolio, and outlook. It references compliance with National Instrument 51-102F1 of the Canadian Securities Administrators, which governs MD&A filings. The text includes forward-looking statements, business description, and detailed discussion of products and market conditions. It explicitly states it should be read in conjunction with audited annual financial statements and unaudited quarterly financial statements. The document length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. The content matches the typical characteristics of a Management Discussion & Analysis report, which provides management's detailed explanation of financial results, business trends, and outlook. Therefore, the appropriate classification is Management Reports (MDA).
2021-05-27 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification form titled 'Form 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE' signed by the CEO of Biocure Technology Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended March 31, 2021. The document explicitly states it is a certification of interim filings, not the filings themselves, and contains no actual financial data or detailed financial statements. It is a regulatory certification related to interim filings, consistent with officer attestation. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is short (3032 characters), and it does not contain substantive financial data or analysis, so it is not an Interim Report (IR). Therefore, the correct classification is Regulatory Filings (RNS).
2021-05-27 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings for a venture issuer, signed by the CFO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended March 31, 2021. The document is primarily an officer certification letter, confirming the accuracy and completeness of the interim filings, but does not contain the actual financial statements or substantive financial data itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3063 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2021-05-27 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.